You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Biocatalytic production of precursors to lutein and zeaxanthin to address age related macular degeneration
SBC: EscaZyme Biochemicals, LLC Topic: NProject Summary Atrophic dry age related macular degeneration AMD is the leading cause of severe loss of vision for those over age Dietary supplements containing lutein and zeaxanthin are recommended by the NEI for those at risk of late AMD There has been a corresponding growth in demand for these two xanthophylls Lutein and zeaxanthin are currently sourced from marigolds grown mostl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity
SBC: COLORADO RESEARCH PARTNERS LLC Topic: 300Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Biacore T100+ for binding affinity measurements to support epitope mapping
SBC: Reclaim Pharmaceutical Waste Management, LLC Topic: 400Project Summary Abstract Protein therapeutics are the fastest growing segment of the pharmaceutical marketyet there are two important challenges associated with the discovery and development of biologic drugsepitope paratope mapping andD structural analysisEpitope and paratope mapping are essential parts of identifying the most therapeutically relevant lead candidates for advancement to in vivo te ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Evidence-Based Pain Intervention for Veterans: Leveraging Mobile and Social Media
SBC: Pro-Change Behavior Systems, Inc. Topic: NCCIHChronic musculoskeletal pain creates a significant public health burden, and Veterans are disproportionately affected. The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), all three conditions (Post-deployment Multi-symptom Disorder (PMD), and other multi-symptom syndromes can complicate and reduce the effectiveness of pain treatment. Furthermore, the ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II
SBC: MBC Pharma, Inc. Topic: NCIProject Summary AbstractThe overall aim of this project is to further develop a novel gemcitabine ibandronate conjugate alone and or as part of a combination therapy for the treatment of osteosarcoma and associated metastasesThe conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone homing bisphosphonate IbandronateThe novel conjugate directly addresses the limi ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Tumor-Specific Fluorescent Cocktail Enables Image-Guided Cytoreductive Surgery
SBC: On Target Laboratories, Inc. Topic: 102Project Summary Abstract Lung cancer remains the leading cause of cancer related deaths worldwideSurgical removal of the tumor is the best therapeutic options for patients with non small cell lung canceryet up toof patients still leave the operating room with deposits of cancer left behindAdvances in CAT and PET scans have provided surgeons with helpful radiographic imaging information prior to su ...
SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Stable Glucagon for Treatment of Hyperinsulinism
SBC: AMIDEBIO, LLC Topic: 200SUMMARY ABSTRACT A series of glucagon analogues will be designedproduced at milligram levelstested for solution stability and both in vitro and in vivo activity with the goal of providing a long term treatment for hyperinsulinism
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease
SBC: EPIVAX, INC. Topic: 200ABSTRACT SignificanceGravesdiseaseGDone of the most prevalent autoimmune diseasesis caused by stimulating autoantibodiesTSAbto the Thyroid Stimulating Hormone ReceptorTSHRresulting in hyperthyroidismCurrent methods for managing hyperthyroidism in GD target excess thyroid hormone secretion by ablation or removal of the thyroid or by blocking thyroid hormone synthesisEach of these therapies is assoc ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Non invasive risk assessment tool for pediatric heart failure
SBC: CORAMIR BIOMEDICAL, INC. Topic: NHLBIABSTRACT Heart Failure HF in pediatric patients is a devastating disease that is difficult to evaluate even with invasive hospital procedures Importantly and unique to the pediatric population approximately of pediatric HF patients spontaneously recover normal heart function within year of diagnosis Unfortunately there is no reliable clinical parameter or biomarker that allows pedia ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of novel Ku targeted kinase inhibitors
SBC: NERX BIOSCIENCES, INC. Topic: 102Title Development of novel Ku targeted kinase inhibitors Abstract DNA PK the DNA dependent protein kinase is a validated target for cancer therapeutics that drives the DNA damage response and plays a critical role in the non homologous end joining NHEJ DNA repair pathway NHEJ is responsible for the repair of DNA double strand breaks DSB particularly those induced by ionizing radiati ...
SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health